NCT00527137 - NESP Pediatric Study | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions

Pre-dialysisEnd Stage Renal Disease

Interventions

DRUG

darbepoetin alfa

Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL

DRUG

rHuEPO

same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL